Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 537

1.

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A, Italiano A, Bouché O, Chauzit E, Duffaud F, Bertucci F, Isambert N, Gautier J, Blay JY, Pérol D; PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO).

Lancet Oncol. 2016 Apr 5. pii: S1470-2045(16)00075-9. doi: 10.1016/S1470-2045(16)00075-9. [Epub ahead of print]

PMID:
27068858
2.

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.

Benson C, Ray-Coquard I, Sleijfer S, Litière S, Blay JY, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla S, Gil T, Piperno-Neumann S, Marréaud S, Dewji MR, van der Graaf WT.

Gynecol Oncol. 2016 Mar 21. pii: S0090-8258(16)30079-8. doi: 10.1016/j.ygyno.2016.03.024. [Epub ahead of print]

PMID:
27012429
3.

Equal access to innovative therapies and precision cancer care.

Buzyn A, Blay JY, Hoog-Labouret N, Jimenez M, Nowak F, Deley ML, Pérol D, Cailliot C, Raynaud J, Vassal G.

Nat Rev Clin Oncol. 2016 Mar 22. doi: 10.1038/nrclinonc.2016.31. [Epub ahead of print] Review.

PMID:
27000960
4.

Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France.

Penel N, Coindre JM, Bonvalot S, Italiano A, Neuville A, Le Cesne A, Terrier P, Ray-Coquard I, Ranchere-Vince D, Robin YM, Isambert N, Ferron G, Duffaud F, Bertucci F, Rios M, Stoeckle E, Le Pechoux C, Guillemet C, Courreges JB, Blay JY.

Eur J Cancer. 2016 May;58:90-6. doi: 10.1016/j.ejca.2016.02.008. Epub 2016 Mar 11.

5.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR.

Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10.

PMID:
26874885
6.

The value of research collaborations and consortia in rare cancers.

Blay JY, Coindre JM, Ducimetière F, Ray-Coquard I.

Lancet Oncol. 2016 Feb;17(2):e62-9. doi: 10.1016/S1470-2045(15)00388-5. Review.

PMID:
26868355
7.

Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.

Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Italiano A, Chevreau C, Bompas E, Collard O, Duffaud F, Rios M, Cupissol D, Adenis A, Ray-Coquard I, Bouché O, Le Cesne A, Bui B, Blay JY, Molimard M.

Eur J Cancer. 2016 Apr;57:31-8. doi: 10.1016/j.ejca.2015.12.029. Epub 2016 Feb 4.

PMID:
26851399
8.

[2015 through the eyes of the Bulletin of Cancer editorial board].

Magné N, Massard C, Bay JO, André T, Blay JY, Goncalves A, Orbach D, Wislez M, Thariat J, Penel N, Rancoule C, Vignot S.

Bull Cancer. 2016 Jan;103(1):3-17. doi: 10.1016/j.bulcan.2015.11.006. Epub 2016 Jan 15. Review. French.

PMID:
26782079
9.

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.

Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, Kang YK, Schöffski P, Schuette J, Soulières D, Blay JY, Goldstein D, Fly K, Huang X, Corsaro M, Lechuga MJ, Martini JF, Heinrich MC.

BMC Cancer. 2016 Jan 15;16:22. doi: 10.1186/s12885-016-2051-5.

10.

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.

Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre JM, Bui-Nguyen B, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Pérol D, Emile JF, Blay JY, Le Cesne A; French Sarcoma Group.

Eur J Cancer. 2016 Jan;52:173-80. doi: 10.1016/j.ejca.2015.10.069. Epub 2015 Dec 11.

PMID:
26687836
11.

Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.

Maillet D, Gan HK, Blay JY, You B, Péron J.

Eur J Cancer. 2016 Jan;52:26-32. doi: 10.1016/j.ejca.2015.08.025. Epub 2015 Nov 27.

PMID:
26630531
12.

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY.

J Clin Oncol. 2015 Dec 20;33(36):4276-83. doi: 10.1200/JCO.2015.62.4304. Epub 2015 Nov 16.

PMID:
26573069
13.

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).

Penel-Page M, Ray-Coquard I, Larcade J, Girodet M, Bouclier L, Rogasik M, Corradini N, Entz-Werle N, Brugieres L, Domont J, Lervat C, Piperno-Neumann S, Pacquement H, Bay JO, Gentet JC, Thyss A, Chaigneau L, Narciso B, Cornille H, Blay JY, Marec-Bérard P.

BMC Cancer. 2015 Nov 5;15:854. doi: 10.1186/s12885-015-1894-5.

14.

Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I.

Nishida T, Tsujimoto M, Takahashi T, Hirota S, Blay JY, Wataya-Kaneda M.

J Gastroenterol. 2015 Oct 29. [Epub ahead of print]

PMID:
26511941
15.

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome.

Brahmi M, Alberti L, Dufresne A, Ray-Coquard I, Cassier P, Meeus P, Decouvelaere AV, Ranchère-Vince D, Blay JY.

BMC Cancer. 2015 Oct 24;15:780. doi: 10.1186/s12885-015-1817-5.

16.

The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.

Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J.

Ann Oncol. 2016 Jan;27(1):192-8. doi: 10.1093/annonc/mdv485. Epub 2015 Oct 19.

PMID:
26483049
17.

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.

Khalifa J, Ouali M, Chaltiel L, Le Guellec S, Le Cesne A, Blay JY, Cousin P, Chaigneau L, Bompas E, Piperno-Neumann S, Bui-Nguyen B, Rios M, Delord JP, Penel N, Chevreau C.

BMC Cancer. 2015 Oct 15;15:700. doi: 10.1186/s12885-015-1697-8.

18.

Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report.

Blay JY, Levard A.

Anticancer Drugs. 2016 Jan;27(1):71-5. doi: 10.1097/CAD.0000000000000286.

PMID:
26457546
19.

Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.

Brahmi M, Thiesse P, Ranchere D, Mognetti T, Pinson S, Renard C, Decouvelaere AV, Blay JY, Combemale P.

PLoS One. 2015 Oct 7;10(10):e0138386. doi: 10.1371/journal.pone.0138386. eCollection 2015.

20.

Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.

Pivot X, Aulagner G, Blay JY, Fumoleau P, Kaliski A, Sarkozy F, Limat S.

Anticancer Drugs. 2015 Nov;26(10):1009-16. doi: 10.1097/CAD.0000000000000287. Review.

PMID:
26352219
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk